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ABSTRACT 
 
Background: The faecal calprotectin (FC) test is a non-invasive marker for gastrointestinal 
inflammation.  
Aim: To determine whether higher FC levels in individuals with quiescent Crohn’s disease 
are associated with clinical relapse over the ensuing 12 months. 
Methods: A single centre prospective study was undertaken in Crohn's disease patients in 
clinical remission attending for routine review. The receiver operating characteristic (ROC) 
curve for the primary endpoint of clinical relapse by 12 months, based on FC at baseline, was 
calculated. Kaplan-Meier curves of time to relapse were based on the resulting optimal FC 
cutoff for predicting relapse. 
Results: Of 97 patients recruited, 92 were either followed up for 12 months without 
relapsing, or reached the primary endpoint within that period. Of these, 10 (11%) had 
relapsed by 12 months. The median FC was lower for non-relapsers, 96µg/g (IQR 39-237), 
than for relapsers, 414µg/g (IQR 259-590), (p=0.005). The area under the ROC curve to 
predict relapse using FC was 77.4%. An optimal cutoff FC value of 240µg/g to predict 
relapse of quiescent Crohn’s had sensitivity of 80.0% and specificity of 74.4%. Negative 
predictive value was 96.8% and positive predictive value was 27.6%.  FC≥240μg/g was 
associated with likelihood of relapse 5.7 (95% CI 1.9-17.3) times higher within 2.3 years than 
lower values (p=0.002). 
Conclusions: In this prospective dataset, FC appears to be a useful, non-invasive tool to help 
identify quiescent Crohn’s disease patients at a low risk of relapse over the ensuing 12 
months. FC of 240µg/g was the optimal cutoff in this cohort.   
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BACKGROUND 
Calprotectin is a calcium and zinc binding protein found in the cytosol of neutrophils. It is 
released at times of cell damage in the gastrointestinal (GI) tract and is resistant to enzymatic 
degradation allowing for measurement in faecal samples. The faecal calprotectin (FC) test 
has been shown to correlate well with faecal excretion of 111indium labeled leucocytes1 and 
with both microscopic and endoscopic evidence of GI inflammation2,3. In addition to its use 
in differentiating irritable bowel syndrome (IBS) from inflammatory bowel disease (IBD)4-8, 
it has been assessed as a marker of mucosal healing9-12. There are seven published studies in 
adult IBD patients that address the issue of FC as a predictor of clinical relapse with ongoing 
medical therapy in quiescent Crohn’s disease (CD)13-19. Higher FC levels were associated 
with a greater risk of relapse for those with Ulcerative colitis (UC)13-17, but discrepant results 
have been seen in CD14,15,19. Furthermore meta-analysis has shown that there is insufficient 
evidence to determine whether FC levels in those with ileal CD can serve to predict relapse20. 
The aim of this study was to prospectively assess the role of FC as a predictive marker of 
relapse within 12 months in those with asymptomatic CD of all phenotypes. 
 
METHODS 
Patients 
In this single centre prospective study, 97 consecutive CD patients in clinical remission 
attending for routine outpatient review between August 2010 and November 2011 were 
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identified and enrolled.  Written informed consent was obtained at time of enrollment.  
Remission was defined as a Crohn’s disease Activity Index (CDAI)21 of <150 points. 
 
We excluded patients with an unclear diagnosis (ie. 'indeterminate colitis’), clinical relapse 
within the preceding 3 months, concomitant serious illness, pregnancy, age<18 years, alcohol 
abuse, non steroidal anti-inflammatory use, and stool culture positivity. 
 
Full ethical approval was awarded on 15 April 2010 by the West of Scotland Research Ethics 
Service (WeSRES) (REC reference 10/S0704/1). 
 
The first FC sample provided by each participant from our recently published study22 on the 
intra-individual variability of FC was used as a baseline value for this prospective follow up 
study. The samples were collected by the patients at home and processed at the biochemistry 
laboratory at Glasgow Royal Infirmary. Patients were reviewed at regular 3-6 monthly 
intervals or at relapse. The primary endpoint was relapse within 12 months, while the 
secondary endpoint was relapse at any time during follow-up. Relapse was defined as an 
unplanned escalation in therapy, progression of disease phenotype by the Montreal 
classification, or hospitalization and/or emergency surgery for active CD. 
 
Biochemistry procedures 
The Roche faecal extraction device was used to prepare and analyze stool samples adhering 
to the manufacturers instructions (Bühlmann calprotectin ELIZA kit). Stool was collected in 
screw-capped plastic containers and received by laboratory within 48 hours of the final stool 
collection. Samples were processed by qualified biochemical scientists with Health 
professionals council registration on site at Glasgow Royal Infirmary. Samples weighing. 
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between 98–102 mg were placed into the extraction tube cap, 4.9ml of extraction buffer was 
then added to all tubes which were recapped and homogenised for 15 minutes on the Alpha 
multi tube vortexer at maximum speed. The homogenate was centrifuged at 3000rpm for 10 
minutes and the supernatants were transferred to plastic tubes and stored at -20oC. The time 
from sampling to preparation and freezing was approximately 1 to 3 days. The supernatants 
were thawed then mixed and centrifuged before analysis with the Bühlmann quantitative 
calprotectin ELISA kit on the Triturus automated ELISA analyser for determination of 
calprotectin concentration in stools. Calprotectin was expressed as micrograms per gram 
(µg/g) of faeces. The faecal samples were stable between 2-8oC for up to 10 days and faecal 
extracts for 4 months at -20oC. 
 
Statistical considerations 
 
The Mann-Whitney or t-test was used, as appropriate, to test for significant differences in 
continuous variables (including FC) between patients who relapsed by 12 months and those 
who did not, while Fisher’s exact test was used for categorical variables. 
 
The sensitivity and specificity of different FC values to predict relapse by 12 months were 
calculated for all those who either reached the primary endpoint within 12 months or were 
followed up for at least 12 months without reaching the primary endpoint, and the resulting 
receiver operating characteristic (ROC) curve plotted.  The corresponding area under the 
curve (AUC) was calculated to represent the overall predictive power of FC in predicting 
relapse up to 12 months later.  The sensitivity, specificity, and negative and positive 
predictive values are presented for the FC cutoff value with the optimal balance of sensitivity 
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and specificity.  Patients who died or were otherwise lost to follow-up before relapsing or 
being followed up for 12 months were excluded from this part of the analysis.   
 
The optimal FC cutoff value was subsequently used to calculate Kaplan-Meier (K-M) 
cumulative event curves of time to relapse for all patients throughout the entire study.  
Patients who did not relapse were censored at end of follow-up.  A Cox proportional hazards 
model was fitted to assess the impact of a FC value above or below the chosen cutoff on time 
to relapse at any point in the study, adjusted for age (in years), gender, any previous surgery 
(yes/no), and stoma (yes/no). 
 
Sample size calculation 
The sample size was calculated for the reliability phase of this study, which is reported in 
detail elsewhere22.  Briefly, we estimated that 95 patients would have 80% power to show a 
95% confidence interval of total width 0.13 around an intraclass correlation coefficient of 0.9 
between the FC values from 3 samples.   
 
RESULTS 
The mean age of all 97 recruited patients at baseline was 47 years (SD 16), 38% were male 
and 20% were smokers. Montreal Classification of CD was as follows: age at diagnosis (A1 
8%, A2 71%, A3 21%), location (L1 16%, L2 36%, L3 47%) and behavior (B1 59%, B2 
30%, B3 11%, p 15%). 
 
Of 97 patients recruited, the care of three individuals was transferred to another centre, one 
died of non-IBD related pathology without reaching an endpoint and one was lost to follow 
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up prior to reaching either the primary endpoint or a follow up of 12 months. The 
sensitivity/specificity part of the analysis therefore included 92 patients.  
 
Of these 92 patients, 10 (10.9%) relapsed within 12 months. Table 1 shows that patients who 
experienced a relapse within 12 months exhibited higher median FC levels at baseline 
(414µg/g; IQR 259-590) than those who did not (96 µg/g; IQR 39-237; p=0.005). There were 
no significant differences in age, gender, surgery, stoma, smoking, age at diagnosis, location, 
behavior or CRP between those who did and did not relapse by 12 months.  Patients were 
more likely to relapse if they were taking chronic steroids, but very small numbers were on 
steroids and the difference was only marginally significant.  There were no other 
relationships between drugs and relapse by 12 months. 
 
Figure 1 shows the ROC curve for predicting relapse by 12 months, with sensitivity and 
specificity of various cutoff values of FC.   The optimal balance of sensitivity and specificity 
corresponded to an FC cutoff value of 240µg/g.  This cutoff gave a sensitivity of 80.0%, 
specificity of 74.4%, negative predictive value of 96.8% and positive predictive value of 
27.6%.  The area under the curve (AUC) to predict CD relapse at 12 months using FC 
determination was 77.4%. 
 
Figure 2 explains the discrepancy between the negative and positive predictive values.  Very 
few patients who relapsed by 12 months had FC of less than 240µg/g.  Therefore if a patient 
had FC<240µg/g they would have a low risk of relapse over the ensuing 12 months.  
However, while many more patients with FC≥240µg/g did relapse, two-thirds of all patients 
with FC of or above 240µg/g did not and this is reflected in the low positive predictive value 
for relapse prediction in our cohort. 
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The selected cutoff of 240µg/g was used to produce Kaplan-Meier (K-M) cumulative event 
curves of time to relapse for all 97 patients and these are presented in Figure 3.  A total of 15 
patients relapsed throughout the study.  The shortest time to relapse was 87 days and the 
longest was 560 days (1.5 years), while the remaining 82 patients were followed up for 
between 98 (3 months) and 849 days (2.3 years) without relapsing.  There is a clear 
separation between the curves, with patients with FCe240µg/g having a substantially shorter 
time to relapse than those with FC below the cutoff.   
 
Table 2 shows the results of the Cox proportional hazards model of FC on time to relapse 
adjusted for demographics.  The model confirmed the difference in time to relapse between 
those with high or low FC exhibited in the K-M curves, with a hazard ratio (HR) for 
FCe240µg/g vs FC<240µg/g of 5.7 (95% CI 1.9-17.3; p=0.004).  Thus, based on our sample, 
a patient with FCe240µg/g is around two to 17 times more likely to relapse within about two 
years than one with FC below 240µg/g. Table 2 also shows that there was no impact of 
demographics on time to relapse.  
 
As exploratory analyses, the 16 patients with ileal only disease and the 35 patients with 
colonic only disease were considered separately.   Three of the 16 ileal patients relapsed 
during the study, at 142, 394 and 560 days, with only one having relapsed by 12 months.  The 
three ileal patients who relapsed at any time during the study had higher median baseline FC 
levels (371 µg/g; IQR 284-741) than the 13 who did not (57 µg/g; IQR 20-101). A Mann 
Whitney test showed marginal statistical non-significance for this difference (P=0.057).  Two 
of the 35 colonic patients relapsed by 12 months, at 94 and 298 days, with a further two 
relapsing later at 470 and 524 days.  The four colonic patients who relapsed at any time 
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during the study had higher median baseline FC levels (424 µg/g; IQR 209-695) than the 31 
who did not (187 µg/g; IQR 48-386), though the difference was not statistically significant 
(p=0.16). 
 
DISCUSSION 
Our prospective dataset, which is the largest yet studied, demonstrates that an FC 
concentration below 240µg/g is predictive of a low risk of clinical relapse within 12 months 
for adults with quiescent CD. The ROC curve analysis revealed that the 240µg/g 
concentration gave an optimal balance of sensitivity (80.0%) and specificity (74.4%).  
Despite a reassuringly high negative predictive value of 96.8% at this cut off, the low positive 
predictive value (27.6%) suggested that FC is most useful as a tool to predict low risk of 
clinical relapse.   
FC is a relatively cheap and non-invasive test making its use attractive in the increasingly 
financially conscious and risk-averse realm of modern health care. Its use is now established 
in differentiating irritable bowel syndrome (IBS) from inflammatory bowel disease (IBD)4-8. 
There is also data supporting its use in evaluating abdominal discomfort23, reducing the need 
for endoscopy in suspected IBD24, assessing treatment response in IBD25,26, predicting 
mucosal healing in IBD9,12,26-27, detecting post operative relapse in CD28-30 and predicting 
response to anti-Tumour necrosis factor (anti-TNF) therapy31-33. 
We have recently shown that FC levels do not vary considerably within individuals with 
quiescent CD on a day to day basis22. This is reassuring if a one off FC is to be used as a tool 
to predict future relapse. It would be beneficial for clinicians to target early effective 
therapies if they could better predict risk. It has been noted that FC may correlate more 
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closely with endoscopic scores than clinical severity scores in CD34, hinting at the potential to 
predict preclinical disease. There are published data on the use of FC levels to predict relapse 
in UC, which consistently show it to be both sensitive and specific13-17, 20.  
There are seven previously published prospective studies that have explored the issue of 
utilising FC concentrations to predict relapse within a 12 month time period in quiescent 
adult CD, showing conflicting results13-19. Three studies showed no statistically significant 
difference between the baseline median FC for relapsers and non-relapsers14,15,19. Costa et al14 
compared FC levels in both UC patients and 38 CD patients14. Although the results were 
higher for those relapsing in UC, the levels in CD were comparable for both relapsers and 
non-relapsers (220.1 vs 220.5µg/g P=0.395). Similarly, in the 65 CD patients studied by 
D’Inca et al15 there was also no statistically significant difference between relapse and non-
relapse median FC levels (207 vs 88 mg/kg P=0.55). They found that the subgroup of colonic 
CD were the only group where FC level was predictive, but the numbers of relapsers in this 
cohort were small (4 of 6 colonic patients relapsed). The study by Laharie et al19 differed 
from the others described, as their 50 CD patients were all in remission 14 weeks post 
infliximab induction. They found no significant difference between week 14 FC levels in 
relapsers vs non-relapsers (200 vs 150µg/g P=NS). This cohort had a high 12-month relapse 
rate (46% vs 12% in our study). 
Conversely, four other studies13,16-18 showed a positive association between FC baseline level 
and risk of relapse. Tibble and colleagues13 use a different and older assay but the FC results 
are equivalent to those of later studies (calprest) when the result is multiplied by a factor of 
five. They showed in 43 CD patients that relapsing patients had higher median baseline FC 
compared with that of non-relapsers (122mg/l – which converts to 610µg/g vs 42mg/l – 
which converts to 220µg/g). They combined the results with UC patients to produce a 
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receiver operator curve (ROC) curve showing that an equivalent FC concentration of over 
250µg/g predicted relapse with a sensitivity of 90% and a specificity of 83%. Garcia-Sanchez 
et al17 studied 66 CD patients and identified a best cut off value of 200µg/g (sensitivity 80%, 
specificity 65%, PPV 46%, and NPV 88%) to predict relapse. They did, however stress that 
relapse predictability was more accurate for colonic CD. Their PPV and NPV values were 
similar to our own which suggest greater accuracy for prediction of remission than relapse. In 
the study by Gisbert et al16, a total of 89 CD patients were included, 13 of whom relapsed. FC 
levels were found to be higher in relapsers (266 vs 145µg/g; P=0.002). Both Gisbert16 and 
Garcia-Sanchez17 drew attention to the fact that a high FC level appeared to be more 
predictive of relapse in colonic disease. Published commentaries35-37 suggested that two of 
the earlier studies13,14 had conflicting results which could be accounted for by differing 
proportions of small bowel CD patients. Given that greater levels of excreted indium111-
labelled leucocytes have been found in colonic vs small bowel CD38, Kallel et al13 were 
prompted to exclude small bowel CD from their analysis of 53 CD patients. Higher median 
FC values were measured at baseline in the relapse group (380.5µg/g cf 155µg/g P<0.001). 
The ROC curve analysis revealed that a level of >340µg/g provided the maximal sum of 
sensitivity (80%) and specificity (90.7%) to predict relapse.  
More recently, Primas and colleagues39 have published an abstract describing 57 CD patients 
post ileocolonic resection. They found that an FC cut off of over 100µg/g 6 months post 
surgery could predict relapse at a median 11 months post surgery with a sensitivity of 93% 
and specificity of 47%. Additionally, a large retrospective analysis of 650 patients (32% 
relapsers) by Kennedy et al40 has been published in abstract form; the primary endpoint was a 
composite of Montreal behaviour progression, hospitalisation for a flare of disease or 
surgery. A total of 211 reached the endpoint within 12 months of whom 57 had a progression 
in Montreal behaviour. They discovered a significant difference between median FC levels in 
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relapsers vs non-relapers (595 vs 320µg/g). It should be noted that neither Primas nor 
Kennedy appear to have identified clinically quiescent patients at baseline as was done in the 
seven published studies described13-19. The patient populations may therefore not be directly 
comparable. 
Louis et al41 studied a very different CD population who had undergone at least 12 months 
infliximab therapy in combination with an antimetabolite. Anti-TNF therapy was withdrawn 
and calprotectin was measured at 2 monthly intervals. Of the 115 patients studied, 85 had FC 
measurements. An FC level >300µg/g at baseline was associated with relapse (hazard ratio 
estimate 2.5 p=0.04). Desuray et al42 looked at this data in greater detail in 113 patients, 
finding a sharp rise in FC within 4 months of relapse with a FC cut off of 305µg/g giving a 
sensitivity of 70% and specificity of 74% for relapse prediction. 
Our own study shows a positive association between FC level and risk of relapse. Our relapse 
rate is relatively low at 11% compared with 18.9% in the group studied by Kallel et al19 and 
58% in the study by Tibble et al13. Our study, and that by Gisbert et al16, included patients on 
continuing biological therapy which may contribute to their similarly low relapse rate 
(14.6%). We chose to study all CD phenotypes in an attempt to establish, in a larger cohort, 
whether an effective cutoff could be determined. Our most effective FC cut off level to 
predict relapse was shown to be 240µg/g, which is similar to that of Tibble et al13 but lower 
than the 340µg/g of Kallel et al19. Given that the latter study19 excluded those without colonic 
disease and indium111 leucocytes are excreted in higher levels in colonic disease38, this could 
explain the higher cut off level. 
In the meta-analysis by Mao et al20, it was commented that there were insufficient available 
data to determine the use of FC to predict relapse in ileal CD. It is more challenging to assess 
proximal gastro intestinal inflammation by endoscopy and patients with inflammatory ileal 
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disease may be less likely to have symptoms than those with colonic CD, leading to a greater 
chance of progressing to fistulising or stricturing disease43. Thus, although FC levels tend to 
be lower in ileal as opposed to colonic disease38, the FC test may well have a greater 
discriminant ability in ileal CD due to the disconnect between clinical symptoms and ileal 
disease activity in this cohort. Interestingly, we found that the difference in median baseline 
FC between relapsers and non-relapsers with ileal CD was large and close to statistical 
significance (371 vs 57µg/g; p=0.057) despite the small number of patients in this subgroup. 
It should be noted that these figures were obtained over an extended period of about two 
years, during which time 3 of the 16 ileal patients had relapsed, since only 1 patient relapsed 
within 12 months. This result suggests that a larger study, perhaps over a longer time period, 
of those with ileal CD would be worthwhile to clarify this potential association.  In our 
subgroup of colonic CD, only two of 31 patients relapsed within 12 months and four in the 
whole study period. Although the mean FC values were higher for the four relapsers (424 vs 
187µg/g), statistical significance was not reached (p=0.16). 
Although some published articles have shown an association between higher baseline C 
reactive Protein (CRP) and risk of relapse18,42,43, others have failed to show this13,14,16. This 
study also shows no association between baseline CRP and the risk of subsequent clinical 
relapse.  It should, however, be noted that this study was not designed to detect such an 
association and approximately half of the patients did not have a baseline CRP measurement. 
We did not show an association with relapse and smoking, but the numbers of those smoking 
at baseline were low (16) and we did not specifically collect data on starting or stopping 
smoking during the study. 
There are additional limitations in our study which merit consideration. Like the previous 
studies described, we used CDAI rather than endoscopy as an objective assessment of disease 
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activity to define remission. This measure has been shown to correlate poorly with more 
objective assesments12. We would argue however that the risk of endoscopy is not justified 
for those in remission as it does not reflect current clinical practice. Furthermore, we 
conducted the study in a tertiary referral institute that may make the findings less applicable 
to the general population, although no novel therapies are used. The investigators were not 
blinded to the FC results, but investigators only based treatment decisions on their clinical 
assessment as there is no prior evidence to change treatment due to FC alone. 
In conclusion, our study, utilising the largest prospective dataset in the current literature, 
provides clearer evidence that adults with quiescent CD with a faecal calprotectin level below 
240µg/g are unlikely to relapse within 12 months, while those with a level of 240µg/g or 
above are substantially more likely to relapse within 12 months. This information can be 
obtained by non-invasive means and can provide both prognostic information for patient and 
clinician and a therapeutic target for physicians treating Crohn’s patients who are in clinical 
remission when attending the outpatient clinic. 
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STUDY HIGHLIGHTS 
What is Current Knowledge 
Faecal calprotectin is useful to predict disease recurrence in ulcerative colitis 
Faecal calprotectin has shown conflicting results when utilised as a predictive marker in 
quiescent Crohn’s  
Faecal calprotectin is thought to be less useful to predict relapse in ileal Crohn’s disease 
 
What is new here? 
Confirmation of the predictive value of faecal calprotectin in Crohn’s in the largest 
prospective study 
Faecal Calprotectin shows potential to predict disease recurrence in quiescent ileal Crohn’s 
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FIGURE LEGENDS  
Figure 1 Receiver operating characteristic (ROC) curve of the sensitivity and specificity of 
FC predicting relapse at 12 months for the 93 patients followed up for at least that length of 
time, based on various cutoffs of FC 
Figure 2 Scatterplot of the FC values of all patients in the study, with those who relapsed by 
12 months marked in red, and those who did not marked in black.  The optimal cutoff of 
240µg/g marked as a dashed line 
Figure 3 Kaplan-Meier (K-M) cumulative event curves of time to relapse in days for all 
patients in the study, stratified by whether their FC was below or above 240µg/g.  Patients 
who did not relapse were censored at end of follow-up and are marked by crosses on the K-M 
curves 
